Analysis of IMPOWER 150 also presented that, for the subgroup of patients with KRAS-mutant lung cancer carrying STK11 and/or Keap1 simultaneously, Atezolizumab combined with Bevacizumab and chemotherapy is an effective first-line treatment [5]. Here, KRAS is linked to lung carcinoma.